Fosun Pharma Subsidiary’s Tao Hong Si Wu Tang Granules Secures NMPA Filing Acceptance

Bulletin Express05-13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration (NMPA) has formally accepted the drug-registration application for Tao Hong Si Wu Tang Granules, an innovative Category 3.1 traditional Chinese medicine developed by its subsidiary Hebei Wanbang Folon Pharmaceutical.

The formulation—sourced from the Qing-dynasty prescription “Tao Hong Si Wu Decoction”—is intended to treat blood-deficiency and blood-stasis syndromes, addressing symptoms such as irregular menstruation, heavy menstrual flow with clots, and abdominal pain. Group R&D expenditure on the project totaled RMB6.96 million as of April 2026.

Market landscape data show only two comparable Tao Hong Si Wu Tang Granule products have received Chinese approval to date (April 2025 and April 2026). Sales figures for 2025 are not yet available from IQVIA CHPA, leaving commercial benchmarks limited.

The granules must still pass GMP compliance inspection and obtain final marketing authorization before production can commence. Management indicated that the filing acceptance alone will not materially affect the Group’s current financial results, and future sales performance will depend on demand, competitive dynamics, and channel penetration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131150128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131150128","market":"us","top_or_hot":-1,"title":"Fosun Pharma Subsidiary’s Tao Hong Si Wu Tang Granules Secures NMPA Filing Acceptance","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration (NMPA) has formally accepted the drug-registration application for Tao Hong Si Wu Tang Granules, an innovative Category 3.1 traditional Chinese medicine developed by its subsidiary Hebei Wanbang Folon Pharmaceutical.</p>\n<p>The formulation—sourced from the Qing-dynasty prescription “Tao Hong Si Wu Decoction”—is intended to treat blood-deficiency and blood-stasis syndromes, addressing symptoms such as irregular menstruation, heavy menstrual flow with clots, and abdominal pain. Group R&D expenditure on the project totaled RMB6.96 million as of April 2026.</p>\n<p>Market landscape data show only two comparable Tao Hong Si Wu Tang Granule products have received Chinese approval to date (April 2025 and April 2026). Sales figures for 2025 are not yet available from IQVIA CHPA, leaving commercial benchmarks limited.</p>\n<p>The granules must still pass GMP compliance inspection and obtain final marketing authorization before production can commence. Management indicated that the filing acceptance alone will not materially affect the Group’s current financial results, and future sales performance will depend on demand, competitive dynamics, and channel penetration.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Subsidiary’s Tao Hong Si Wu Tang Granules Secures NMPA Filing Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Subsidiary’s Tao Hong Si Wu Tang Granules Secures NMPA Filing Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-13 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration (NMPA) has formally accepted the drug-registration application for Tao Hong Si Wu Tang Granules, an innovative Category 3.1 traditional Chinese medicine developed by its subsidiary Hebei Wanbang Folon Pharmaceutical.</p>\n<p>The formulation—sourced from the Qing-dynasty prescription “Tao Hong Si Wu Decoction”—is intended to treat blood-deficiency and blood-stasis syndromes, addressing symptoms such as irregular menstruation, heavy menstrual flow with clots, and abdominal pain. Group R&D expenditure on the project totaled RMB6.96 million as of April 2026.</p>\n<p>Market landscape data show only two comparable Tao Hong Si Wu Tang Granule products have received Chinese approval to date (April 2025 and April 2026). Sales figures for 2025 are not yet available from IQVIA CHPA, leaving commercial benchmarks limited.</p>\n<p>The granules must still pass GMP compliance inspection and obtain final marketing authorization before production can commence. Management indicated that the filing acceptance alone will not materially affect the Group’s current financial results, and future sales performance will depend on demand, competitive dynamics, and channel penetration.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1131150128","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131150128","pubTimestamp":1778672568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration (NMPA) has formally accepted the drug-registration application for Tao Hong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药子公司桃红四物汤颗粒获NMPA备案受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration (NMPA) has formally accepted the drug-registration application for Tao Hong Si Wu Tang Granules, an innovative Category 3.1 traditional Chinese medicine developed by its subsidiary Hebei Wanbang Folon Pharmaceutical.\nThe formulation—sourced from the Qing-dynasty prescription “Tao Hong Si Wu Decoction”—is intended to treat blood-deficiency and blood-stasis syndromes, addressing symptoms such as irregular menstruation, heavy menstrual flow with clots, and abdominal pain. Group R&D expenditure on the project totaled RMB6.96 million as of April 2026.\nMarket landscape data show only two comparable Tao Hong Si Wu Tang Granule products have received Chinese approval to date (April 2025 and April 2026). Sales figures for 2025 are not yet available from IQVIA CHPA, leaving commercial benchmarks limited.\nThe granules must still pass GMP compliance inspection and obtain final marketing authorization before production can commence. Management indicated that the filing acceptance alone will not materially affect the Group’s current financial results, and future sales performance will depend on demand, competitive dynamics, and channel penetration.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131150128","isCrawlerRequest":true}